Quince Therapeutics Engages LifeSci Capital, Shares Soar 54% in Premarket
Quince Therapeutics has retained LifeSci Capital as exclusive advisor to explore strategic alternatives including partnerships, joint ventures and liability restructuring. The stock climbed 54.15% in premarket trading on volume of 29.84 million, despite a 90.91% year-over-year decline and oversold technical indicators.
1. Exclusive Advisor Engagement
Quince Therapeutics engaged LifeSci Capital as its exclusive financial advisor to explore strategic alternatives aimed at maximizing shareholder value. Proposed options include potential partnerships, joint ventures and restructuring of the company’s liabilities.
2. Premarket Surge and Volume
Shares jumped 54.15% to $0.20 in premarket trading on a session volume of 29.84 million shares, compared with an average volume of 2.92 million. The surge reflects renewed market interest following the advisor appointment.
3. Technical Weakness and Indicators
The stock is trading 89.6% below its 20-day simple moving average and 91.2% below its 100-day average, with a 12-month share decline of 90.91%. An RSI of 22.15 signals oversold conditions while the MACD remains below its signal line, indicating continued bearish momentum.